Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.
News|Videos|June 26, 2025
APPULSE-PNH: Oral Iptacopan Monotherapy Demonstrates Clinically Meaningful Hemoglobin (Hb) Increases in Patients (Pts) With Paroxysmal Nocturnal Hemoglobinuria (Pnh) and Hb ≥10 G/Dl Oo Anti-C5 Therapy
Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, presents results from the phase 3b APPULSE-PNH trial at the 2025 EHA Congress in Milan, Italy. The data demonstrate that, in patients with PNH and hemoglobin ≥10 g/dL who switched from anti-C5 therapy to iptacopan, iptacopan was superior in improving hemoglobin levels from baseline.
Advertisement
Advertisement
Related to this article
Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.
Zanubrutinib plus R-BAP produced responses in both younger and older patients with previously untreated mantle cell lymphoma.
Breast oncologists weigh the future role of radiographic progression vs liquid biopsy in the timing of therapeutic shifts in metastatic breast cancer.
Sylvester cancer researchers became wildland firefighters themselves to study, from the inside, cancer risks tied to the job.
The FDA has granted breakthrough device designation to Merlin CP-GEP, a clinicopathologic gene expression profile test for early-stage cutaneous melanoma.
Brian Myre, MD, discusses phase 1 data with the novel in situ SYNC-T Therapy SV-102 and the ongoing phase 2 LEGION-100 study in prostate cancer.
Drs Nunnery and Iyengar discuss FAQs about the metabolic effects of breast cancer therapy and the expanding role of GLP-1 receptor agonists in oncology.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies
2
SERENA-6 Controversies Push the Breast Cancer Field to Consider the Future Role of ctDNA-Guided Treatment Decisions
3
GLP-1 Receptor Agonists, Endocrine Therapy, and Metabolic Health Comprise Holistic Breast Cancer Care
4
SYNC-T SV-102 Employs Novel Mechanism to Target Immunologically ‘Cold’ Tumors in Advanced Metastatic Prostate Cancer
5